CANCER-ID was a European consortium focused on validating blood-based biomarkers, including circulating tumor cells (CTCs), ctDNA, cfmiRNAs, and exosome-bound miRNA, for assessing treatment response and detecting drug targets in non-small cell lung carcinoma (NSCLC) and HER2-positive metastatic breast cancer. Our group spearheaded tasks related to CTC enumeration in DLA products and the comparison of single CTC isolation methods. Funded by the Innovative Medicines Initiative Joint Undertaking (IMI JU), this project aimed to advance personalized cancer treatment and diagnostics. (https://www.imi.europa.eu/projects-results/project-factsheets/cancer-id)